News

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

"As we commemorate Black History Month, it is an opportune time to highlight the contributions of Black clinicians while acknowledging past and current shortcomings as well as the imperative to strive for improved equity for clinicians and patients alike."

Explore 10 sides of love in 10 captivating films.

Clinical trial compares outcomes with behavioral activation psychotherapy or antidepressant medication for depression in patients with heart failure.

Available evidence from preclinical studies indicates that semaglutide shows promise for treating Alzheimer disease and Parkinson disease.

One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.

The treatment's PDUFA date is set for August 11, 2024.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Love: a distraction or inspiration?

"I refuse to see sexual violence as a 'women’s issue.' It is a human issue and should be addressed as one."

How do work and psychiatry evolve and influence each other?

Learn more about the inaugural Black Youth Mental Health Clinical Case Conference Series at Yale Child Study Center, a 6-session event in 2024, that focuses on improving mental health care for Black youth and their families.

Welcome to the Year of the Dragon! What does it mean?

Take a look back at our recent coverage relating to our February content theme.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

New positive data on TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.

Football and mental health care: Sometimes predictions work, but it is also worth taking some chances and having backup plans.

New research finds whole-family collaborative care digital mental health interventions help manage disordered eating behaviors in adolescents aged 13-17.

One reader argues against the limits of the Goldwater Rule.

How has psychiatry affected the role of being a parent? What makes a good parent?

“I wish I were dead.” Researchers performed a meta-analysis of psychological pain and suicidality in patients with depression.

The grant programs are aimed at supporting treatment services for pregnant and postpartum individuals and individuals involved in treatment drug courts.

A comment on the Goldwater Rule from our readers…

What makes a winning team, in football and in health care?

Our new column on AI in psychiatry explores the future of mental health care.

A new study correlates reduced serotonin transporter and increased amyloid-ß deposition with cognitive deficits in mild cognitive impairment, suggesting a role for serotonergics in early Alzheimer disease.

Does seeing art live vs online impact the brain differently?

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

What is new in research on depression?